Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
/
Haleon
HLN
Haleon
Aging Global Demand And Digital Reach Will Drive Consumer Healthcare
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
08 Jun 25
Updated
23 Jul 25
1
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
UK£5.03
27.5% undervalued
intrinsic discount
23 Jul
UK£3.65
Loading
1Y
-1.8%
7D
1.1%
Author's Valuation
UK£5.0
27.5% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
UK£5.0
27.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
13b
2019
2021
2023
2025
2027
2028
Revenue UK£12.8b
Earnings UK£2.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.11%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.82%
Calculation
UK£2.10b
Earnings '28
x
25.41x
PE Ratio '28
=
UK£53.41b
Market Cap '28
UK£53.41b
Market Cap '28
/
8.82b
No. shares '28
=
UK£6.05
Share Price '28
UK£6.05
Share Price '28
Discounted to 2025 @ 6.64% p.a.
=
UK£4.99
Fair Value '25